PDF
Efficacy of small molecules against the severe acute respiratory syndrome coronavirus 2 XBB1.16 and XBB1.9.2.1
Lunzhi Yuan1(
), Xuan Liu2, Song Li3, Wu Zhong3(), Ningshao Xia1()
PDF
Efficacy of small molecules against the severe acute respiratory syndrome coronavirus 2 XBB1.16 and XBB1.9.2.1
), Xuan Liu2, Song Li3, Wu Zhong3(), Ningshao Xia1()| 1 | R Uraki, M Ito, M Kiso, et al. Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate. Lancet Infect Dis. 2023;23(4):402-403. |
| 2 | E Takashita, N Kinoshita, S Yamayoshi, et al. Efficacy of antiviral agents against the SARS-CoV-2 Omicron subvariant BA.2. New Engl J Med. 2022;386(15):1475-1477. |
| 3 | E Takashita, S Yamayoshi, Y Kawaoka. Efficacy of antiviral agents against the Omicron subvariant BA.2.75. New Engl J Med. 2022;387(13):1236-1238. |
| 4 | YM Hu, EM Lewandowski, HZ Tan, et al. Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir. ACS Central Sci. 2023;9(8):1658-1669. |
| 5 | Y Kaku, Y Kosugi, K Uriu, et al. The Genotype to Phenotype Japan (G2P-Japan) Consortium, Kei Sato. Antiviral efficacy of the SARS-CoV-2 XBB breakthrough infection sera against Omicron subvariants including EG.5. Lancet Infect Dis. 2023;23(10):e395-e396. |
| 6 | T Tamura, J Ito, K Uriu, et al. Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants. Nat Commun. 2023;14(1):2800. |
/
| 〈 |
|
〉 |
AI Summary
